DIR Return Create A Forum - Home
       ---------------------------------------------------------
       Camelot Fantasies 
  HTML https://castleknights.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: Stocks Universe
       *****************************************************
       #Post#: 68861--------------------------------------------------
       INNV
       By: Clay Death Date: November 17, 2017, 8:38 am
       ---------------------------------------------------------
  HTML https://finance.yahoo.com/news/seethruequity-issues-innovus-pharmaceuticals-innv-110000464.html
       #Post#: 68862--------------------------------------------------
       Re: INNV
       By: Clay Death Date: November 17, 2017, 8:39 am
       ---------------------------------------------------------
       NEW YORK, NY / ACCESSWIRE / November 17, 2017 / SeeThruEquity, a
       leading independent equity research and corporate access firm
       focused on smallcap and microcap public companies, today
       announced it has issued an update on Innovus Pharmaceuticals,
       Inc. (INNV) with a price target of $0.65.
       The report is available here: INNV November 2017 Update Note.
       Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a
       fast-growing commercial stage pharmaceutical company that
       delivers safe, innovative and effective over-the-counter (OTC)
       medicine and consumer care products to improve men and women's
       health, respiratory disease and vitality.
       Investment Highlights
       On November 14, 2017, Innovus reported 3Q17 results which
       demonstrated both sequential and YoY revenue growth, reflecting
       a growing portfolio of OTC products. Importantly, the company
       officially launched its newest and highest profile product line,
       FlutiCare™, a nasal steroid which management expects to have a
       transformational impact on the company. Highlights were as
       follows:
       FlutiCare™ launches. INNV announced the official launch of
       FlutiCare™ OTC in the US on November 14, 2017. FlutiCare™ was
       the leading prescribed nasal steroid and form, and its OTC
       formulation is expected to be a significant driver of growth for
       Innovus in 4Q17 and 2018.
       Innovus revenues rose by 18% to a record $2.2mn in 3Q17 versus
       $1.9mn in 3Q16 and were up sequentially from $2.0mn in 2Q17.
       Revenues for the first nine months of 2017 were $6.4mn, more
       than double $3.1mn in the comparable year-ago period.
       Innovus is likely to come in towards the bottom of its guidance
       for $10- $15mn in revenues in 2017, due in part to the impact of
       weather disruptions in key markets.
       *****************************************************